Related Experiment Videos
[Sentinel lymph node for breast cancer: remove less to know more]
L Fortunato1, C Benzoni, M Amini
1Modulo di Chirurgia Oncologica, Ospedale M. G. Vannini, Rome, Italy. lfortunato@tiscalinet.it
Minerva Chirurgica
|September 25, 2001
Summary
Sentinel lymph node (SLN) biopsy accurately identifies breast cancer spread, reducing the need for axillary lymphadenectomy in most patients. This minimally invasive technique ensures precise staging while improving patient outcomes.
Area of Science:
- Oncology
- Surgical Pathology
- Diagnostic Imaging
Context:
- Breast cancer staging is critical for treatment planning.
- Axillary lymph node status significantly impacts prognosis.
- Sentinel lymph node biopsy (SLN) is an evolving technique for staging breast cancer.
Purpose:
- To evaluate the efficacy and reproducibility of sentinel lymph node (SLN) biopsy in a community hospital setting.
- To determine the value of SLN biopsy in patients with early-stage breast cancer.
- To assess the potential to reduce routine axillary lymphadenectomy.
Summary:
- A prospective study of 108 breast cancer patients (tumor <3cm) utilized a combined technetium-99m and Patent Blue dye method for SLN identification.
- The SLN identification success rate was 94%, with 98% correlation to final axillary status.
- In 61% of patients with positive axillary nodes, the SLN was the only positive node; 62% of patients could have avoided axillary dissection based on negative SLN results.
Impact:
- SLN biopsy is a highly accurate and reproducible procedure for breast cancer staging.
- The findings suggest that routine axillary lymphadenectomy can be avoided in a majority of breast cancer patients.
- This approach minimizes surgical morbidity and improves patient quality of life.